Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation.
Diabetes is associated with a hypercoagulable state that contributes to macrovascular complications, including cardiovascular events. The glycation reaction, a consequence of chronic hyperglycemia, has also been implicated in the pathogenesis of diabetic complications. Glycated proteins have receptors on monocytes and generate reactive oxygen species that can regulate the expression of a number of genes. As abnormal monocyte expression of tissue factor (TF), the main initiator of the coagulation cascade, is responsible for thrombosis in a number of clinical settings, we studied the effect of glycated albumin on monocyte TF expression. Mononuclear cells were incubated with glycated albumin for 24 hours, and monocyte TF activity was measured with a plasma recalcification time assay; TF antigen was measured by ELISA and TF mRNA by RT-PCR. Glycated albumin induced blood monocyte expression of the procoagulant protein TF at the mRNA level. Oxidative stress appeared to be involved in this effect, as the antioxidant N-acetylcysteine diminished TF mRNA accumulation in stimulated monocytes. Hydroxyl radicals, which may be generated inside cells from H2O2 via the Fenton reaction, also appeared to be involved in this effect, as hydroxyl radical scavengers downregulated TF activity and antigen levels (but not TF mRNA). Finally, the involvement of activated protein tyrosine kinase in the transmission of the signal from the membrane to the nucleus was suggested by the inhibitory effect of herbimycin A. These results point to a new mechanism for the hypercoagulability often described in diabetic patients and suggest that antioxidants or protein tyrosine kinase inhibitors might be of therapeutic value in this setting.
Khechai
F
F
INSERM U294, CHU Xavier Bichat, Paris, France.
Ollivier
V
V
Bridey
F
F
Amar
M
M
Hakim
J
J
de Prost
D
D
D000111:Acetylcysteine / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D016227:Benzoquinones; D048909:Diabetes Complications; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D017127:Glycation End Products, Advanced / Q000494:pharmacology*; D006031:Glycosylation; D006801:Humans; D017665:Hydroxyl Radical / Q000494:pharmacology; D047029:Lactams, Macrocyclic; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D018384:Oxidative Stress; D010766:Phosphorylation; D011499:Protein Processing, Post-Translational; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011809:Quinones / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D017828:Rifabutin / Q000031:analogs & derivatives; D012709:Serum Albumin / Q000494:pharmacology*; D000075462:Serum Albumin, Human; D015398:Signal Transduction / Q000187:drug effects*; D019851:Thrombophilia / Q000209:etiology / Q000378:metabolism; D013925:Thromboplastin / Q000096:biosynthesis* / Q000235:genetics
D000975:Antioxidants; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D016166:Free Radical Scavengers; D017127:Glycation End Products, Advanced; D047029:Lactams, Macrocyclic; D011809:Quinones; D012333:RNA, Messenger; D012709:Serum Albumin; C109748:advanced glycation end products-human serum albumin; D017828:Rifabutin; D017665:Hydroxyl Radical; C020754:herbimycin; D013925:Thromboplastin; D011505:Protein-Tyrosine Kinases; D000111:Acetylcysteine; D000075462:Serum Albumin, Human